NCT03700567 (LOTA-I) is a NA clinical trial of low temperature contrast in Unstable Angina Pectoris, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT03700567?

NCT03700567 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What drugs are being tested in NCT03700567?

Interventions in NCT03700567: low temperature contrast.

What condition does NCT03700567 study?

NCT03700567 studies Unstable Angina Pectoris.

Is NCT03700567 still recruiting?

NCT03700567 is currently completed. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT03700567: LOTA-I

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Low Temperature Contrast in UAP Patients During PCI (LOTA-I)

Completed NA Last updated 18 November 2023

What this trial tests

NA trial testing low temperature contrast in Unstable Angina Pectoris in 440 participants. Completed in 1 July 2023.

Timeline

1 August 2018

Primary endpoint
1 July 2023

1 July 2023

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	440
Start date	1 August 2018
Primary completion	1 July 2023
Estimated completion	1 July 2023
Sites	7 locations across China

Drugs / interventions tested

low temperature contrast

Conditions studied

Unstable Angina Pectoris — all drugs for Unstable Angina Pectoris →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 18 to 100, any sex, with Unstable Angina Pectoris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Percutaneous coronary intervention (PCI) has become one of the main treatments for rapid recovery of revascularization in patients with coronary heart disease (CHD). PCI has some advantages, such as easy operation, small trauma and rapid recovery. It can significantly improve myocardial ischemic symptom and reduce the incidence of cardiovascular adverse events in CHD patients. However, many studies have found that the incidence of PCI-related myocardial injury is relatively high, and affect the efficacy of PCI and prognosis in patients with unstable angina pectoris (UAP). A meta-analysis of a total of 7578 patients with UAP from 15 studies who underwent PCI was found to have a 28.7% increase in myocardial biomarkers after PCI. The objective of this randomized control trial is to gain a clinical insight on the use of low temperature contrast for the treatment of PCI-related myocardial injury in UAP patients. The primary objective is assess efficacy and safety of low temperature contrast for the treatment of PCI-related myocardial injury in UAP patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Unstable Angina Pectoris

Currently open trials in the same condition.

NCT01218776 — International Survey of Acute Coronary Syndromes · recruiting

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03700567 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03700567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing